President Donald Trump's sweeping executive order aimed at curbing state-level artificial intelligence (AI) regulation is triggering fierce political backlash, legal questions, and sharply divided reactions across Washington, labor groups, and Silicon Valley. Trump Pushes Single National AI Framework Trump on…
The global conversation around digital assets is shifting from speculative market cycles to deeper questions about blockchain surveillance, compliance and the future of privacy. As regulators intensify their focus on how cryptocurrency transactions are monitored, the stakes are rising for…
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro. • Tenaya Therapeutics stock is feeling bearish pressure. What’s pressuring…
The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplinza (inebilizumab-cdon) for generalized myasthenia gravis (gMG). The approval covers adult patients who are anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK) antibody positive. gMG is a…
Cannabis stocks haven't moved like this in years, and it took a rare one-two punch to jolt the sector back to life: a Washington Post scoop hinting that President Donald Trump wants to reclassify marijuana into Schedule III — and…
On Thursday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) supplemental New Drug Application for gepotidacin as an oral option for uncomplicated urogenital gonorrhoea. GSK stock is showing upward bias. What’s the outlook for GSK shares? Gonorrhoea is…
The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) New Drug Application (NDA) for the use of an oral pellet formulation of once-daily Orladeyo (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE)…
Records from December 11, 2025 indicate that Representative Julie Johnson of Texas made a sale of 3M (NYSE:MMM), valued between $63,063 and $945,000, with the transaction dated November 13, 2025 and filed in December. As of now, 3M shares are…
Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s (NYSE:LLY) experimental oral weight-loss treatment, orforglipron. The initiative is part of the National Priority Voucher program,…
The stock prices of major cannabis companies like Tilray Brands (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) skyrocketed 34.88% and 27.46%, respectively, in premarket trading on Friday, following reports of President Donald Trump‘s plans to relax federal regulations on marijuana. Meanwhile, Aurora Cannabis Inc. (NASDAQ:ACB)…